Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Smoking Behavior in Schizophrenia Clear all
Recruiting Phase 4 Interventional

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

NCT03495024
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Interventions
Varenicline
Drug
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 2, 2026, 5:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality

NCT01031433
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic

NCT02128919
View directory record Official record
Conditions
Schizophrenia, Cognition, Cigarette Smoking
Interventions
tDCS
Device
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

NCT02420015
View directory record Official record
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Nicotine replacement therapy, Bupropion, cognitive-behavioral smoking cessation counseling, Mobile Contingency Management, Stay Quit Coach, SMS text messaging
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Music to Reduce Use of Smoking in Patients With Schizophrenia

NCT03190161
View directory record Official record
Conditions
Schizophrenia, Nicotine Dependence, Smoking, Tobacco
Interventions
Music session
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness

NCT04011280
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Nicotine Dependence
Interventions
Varenicline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 2, 2026, 5:51 AM EDT
Terminated Phase 2 Interventional Results available

Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1

NCT03507127
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 2Phase 3 Interventional

Galantamine for Cognitive Deficits in Schizophrenia

NCT00463879
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 12, 2007 · Synced Oct 2, 2026, 5:51 AM EDT
Completed No phase listed Observational

Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia

NCT03075202
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
e-cigarette, brand name JUUL
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

NCT00644969
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Aurora, Colorado • Farmington, Connecticut • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 2, 2026, 5:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia

NCT01034085
View directory record Official record
Conditions
Nicotine Dependence, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia

NCT01010477
View directory record Official record
Conditions
Smoking Cessation, Schizophrenia
Interventions
Nicotine Nasal Spray, Behavioral counseling
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 2, 2026, 5:51 AM EDT
Not listed Not applicable Interventional

Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia

NCT00231101
View directory record Official record
Conditions
Smoking Behavior in Schizophrenia
Interventions
Quetiapine
Drug
Lead sponsor
Arthur P. Noyes Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2006 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Novel Smoking Cessation Drug for Schizophrenia

NCT02230384
View directory record Official record
Conditions
Smoking Cessation
Interventions
Active JNJ Drug, Placebo Pill
Drug
Lead sponsor
K.N. Roy Chengappa
Other
Eligibility
18 Years to 66 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 2, 2026, 5:51 AM EDT
Terminated Phase 4 Interventional

Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia

NCT01576640
View directory record Official record
Conditions
Nicotine Dependence, Schizophrenia
Interventions
NRT, Bupropion SR 150mg bid, Relapse Prevention-Oriented Cognitive Behavioral Therapy
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Varenicline and Smoking Cessation in Schizophrenia

NCT01111149
View directory record Official record
Conditions
Schizophrenia, Smoking Cessation
Interventions
Sugar Pill, Varenicline, Bupropion HCl
Other · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 4 Interventional

Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia

NCT00727103
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Alcohol Dependence, Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 4 Interventional

Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia

NCT00320723
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
bupropion, transdermal nicotine patch
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2009 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia

NCT00770237
View directory record Official record
Conditions
Schizophrenia, Nicotine Dependence
Interventions
Smoking Cues, Neutral Cues
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

NCT00802919
View directory record Official record
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Varenicline, Placebo for varenicline
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

Effects of Atomoxetine on Cognitive Function in Schizophrenia

NCT00420498
View directory record Official record
Conditions
Schizophrenia, Cognition, Smoking
Interventions
Atomoxetine (Strattera™)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 12, 2007 · Synced Oct 2, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness

NCT01779440
View directory record Official record
Conditions
Mental Illness, Tobacco Smoking, Psychotic Disorders
Interventions
Electronic Decision Support System
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 30 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Manchester, New Hampshire • Nashua, New Hampshire • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 2, 2026, 5:51 AM EDT